CROSBY Research – MicroPort CardioFlow (2160 HK): Innovative structural heart disease implantation specialist

07 Nov 2022

Listed in 2021, MicroPort CardioFlow (MCF) is a medical device company focusing on the R&D, commercialization of innovative transcatheter and surgical solutions for valvular heart diseases. The company’s products help to improve the lives of valvular heart disease patients by providing optimal and affordable medical solutions through continuous innovation.

← CROSBY Research – Xtep (1368 HK/BUY): Retail growth slowdown in Sept
CROSBY Research – China Suntien Green Energy (956 HK/BUY): 3Q22 revenue up 22.8% YoY →